Vedanta's lead program, VE303, is an orally administered live biotherapeutic product comprising a defined consortium of eight bacterial strains, developed to prevent recurrent Clostridioides difficile infection. VE303 is produced from pure, clonal bacterial cell banks to yield a standardized powdered drug product and has received FDA Orphan Drug designation (2017) and Fast Track designation (2023). The registrational Phase 3 RESTORATiVE303 trial is randomized, double-blind and placebo-controlled with a 2:1 randomization and a primary endpoint of CDI recurrence rate at Week 8. RESTORATiVE303 is enrolling across more than 150 sites in about 20 countries, has passed a DMC interim analysis recommending continuation, and is expected to complete enrollment in H2 2026 with topline data in H1 2027. Vedanta is funding the trial through the recent $60M financing package and supplemental BARDA funding. The company intends the RESTORATiVE303 study to form the basis for a Biologics License Application to the U.S. FDA.

Total raised

$394M

Funding rounds

15

Latest round

Equity

Latest activity

Aug 2026